Novavax entered 2025 with a significantly strengthened financial position and renewed investor confidence. The first quarter results show not only an increase in revenue, but also a significant turnaround towards profitability. Key drivers were exceptional revenue from contract terminations and strong partnership income, particularly with Sanofi. In addition, the company successfully continued to restructure costs, resulting in a noticeable reduction in operating expenses and an overall improvement in financial health.

Beyond the numbers, however, Novavax $NVAX is showing a clear strategic vision. The company is advancing the development of next-generation combination vaccines, strengthening key international partnerships, and gaining important regulatory feedback that could pave the way for additional milestone payments. With growing investor support and a revised 2025 outlook, the company appears poised to return to being a major player in the biotech sector.

How was the last quarter?

N…